Why the study?
Does sotatercept reduce pulmonary vascular resistance in patients with combined post- and pre-capillary pulmonary hypertension associated with heart failure with preserved ejection fraction?
RCT (n=164)
Placebo-controlled
1:1:1
Yes
Does sotatercept reduce pulmonary vascular resistance in patients with combined post- and pre-capillary pulmonary hypertension associated with heart failure with preserved ejection fraction?
Sotatercept demonstrates both clinical and hemodynamic benefits, including significantly reduced pulmonary vascular resistance, in patients with combined post- and pre-capillary pulmonary hypertension associated with HFpEF.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Gozdecki et al. (2026) conducted an RCT in Combined post- and pre-capillary pulmonary hypertension (CpcPH) associated with heart failure with preserved ejection fraction (HFpEF) (n=164). Sotatercept vs. Placebo was evaluated on Change in pulmonary vascular resistance (PVR) at 24 weeks (Hodges-Lehmann shift -1.02, 95% CI -1.81 to -0.23, p=0.004).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: